GetTopicDetailResponse(id=4ba710418d0, topicName=Karyopharm, introduction=Karyopharm, content=null, image=null, comments=5, allHits=1210, url=https://h5.medsci.cn/topic?id=10418, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=75596, tagList=[TagDto(tagId=75596, tagName=Karyopharm)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1509636, encodeId=e524150963639, content=<a href='/topic/show?id=4ba710418d0' target=_blank style='color:#2F92EE;'>#Karyopharm#</a>, objectTitle=FDA批準Karyopharm的Xpovio（selinexor）用于治療多發(fā)性骨髓瘤, objectType=article, longId=204714, objectId=6286204e1417, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6286204e1417, replyNumber=0, likeNumber=110, createdTime=2020-12-22, rootId=0, userName=mxj1971615, userId=c85310112774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6286204e1417, moduleTitle=FDA批準Karyopharm的Xpovio（selinexor）用于治療多發(fā)性骨髓瘤, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=6286204e1417)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509635, encodeId=94a21509635d6, content=<a href='/topic/show?id=4ba710418d0' target=_blank style='color:#2F92EE;'>#Karyopharm#</a>, objectTitle=Karyopharm的口服核出口選擇性抑制劑XPOVIO針對多發(fā)性骨髓瘤的III期臨床試驗達到終點, objectType=article, longId=189451, objectId=9d821894518e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d821894518e, replyNumber=0, likeNumber=63, createdTime=2020-03-07, rootId=0, userName=mxj1971615, userId=c85310112774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d821894518e, moduleTitle=Karyopharm的口服核出口選擇性抑制劑XPOVIO針對多發(fā)性骨髓瘤的III期臨床試驗達到終點, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=9d821894518e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509634, encodeId=c4b81509634e3, content=<a href='/topic/show?id=4ba710418d0' target=_blank style='color:#2F92EE;'>#Karyopharm#</a>, objectTitle=FDA接受Karyopharm的口服核出口選擇性抑制劑XPOVIO的補充新藥申請，用于治療復(fù)發(fā)或難治的彌漫性大B細胞淋巴瘤, objectType=article, longId=188486, objectId=9acb18848624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9acb18848624, replyNumber=0, likeNumber=65, createdTime=2020-02-22, rootId=0, userName=mxj1971615, userId=c85310112774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9acb18848624, moduleTitle=FDA接受Karyopharm的口服核出口選擇性抑制劑XPOVIO的補充新藥申請，用于治療復(fù)發(fā)或難治的彌漫性大B細胞淋巴瘤, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=9acb18848624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509633, encodeId=8e771509633d4, content=<a href='/topic/show?id=4ba710418d0' target=_blank style='color:#2F92EE;'>#Karyopharm#</a>, objectTitle=FDA批準Karyopharm的核輸出抑制劑Xpovio用于治療復(fù)發(fā)或難治的多發(fā)性骨髓瘤, objectType=article, longId=174802, objectId=d82e1e480215, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d82e1e480215, replyNumber=0, likeNumber=85, createdTime=2019-07-06, rootId=0, userName=mxj1971615, userId=c85310112774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d82e1e480215, moduleTitle=FDA批準Karyopharm的核輸出抑制劑Xpovio用于治療復(fù)發(fā)或難治的多發(fā)性骨髓瘤, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d82e1e480215)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509632, encodeId=ea5c1509632bd, content=<a href='/topic/show?id=4ba710418d0' target=_blank style='color:#2F92EE;'>#Karyopharm#</a>, objectTitle=德琪醫(yī)藥與Karyopharm Therapeutics正式啟動戰(zhàn)略合作，正式進軍血液腫瘤領(lǐng)域, objectType=article, longId=139417, objectId=2cad13941ef3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cad13941ef3, replyNumber=0, likeNumber=69, createdTime=2018-05-31, rootId=0, userName=mxj1971615, userId=c85310112774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cad13941ef3, moduleTitle=德琪醫(yī)藥與Karyopharm Therapeutics正式啟動戰(zhàn)略合作，正式進軍血液腫瘤領(lǐng)域, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2cad13941ef3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
